The Epigenetic Biomarker γH2AX: From Bench to Clinical Trials

Emmy P. Rogakou; Vassilios Papadakis; George Chrousos

doi:10.1007/978-3-319-25325-1_4

Back

Shared by

George Chrousos

National Technical University of Athens

The Epigenetic Biomarker γH2AX: From Bench to Clinical Trials

Chapter In A Book 2016 en

Related publications

Article2022

Statins to prevent pacing-induced cardiomyopathy: Evidence from the bench applied to clinical studies

Yu‐Sheng Lin, Professor Gregory Lip, Wan‐Chun Ho, Chung‐Sheng Shi, Meng‐Hung Lin, Ting‐Yu Kuo, Chang‐Min Chung, Shih‐Tai Chang, Yung‐Lung Chen, Huang‐Chung Chen, Wei‐Chieh Lee, Mien‐Cheng Chen

Article

Authors

ER
Emmy P. Rogakou
VP
Vassilios Papadakis
George Chrousos
National And Kapodistrian University Of Athens

Discussion(0)

Sign in to like and join the discussion.

No comments yet. Be the first to comment.

1996

Hypertension and outcomes research From clinical trials to clinical epidemiology

Bruce M. Psaty, David S. Siscovick, Noel S. Weiss, Thomas D. Koepsell, Frits R. Rosendaal, D. Y. Lin, Susan R. Heckbert, Edward H. Wagner, Curt D. Furberg

American Journal of Hypertension

Article1996

Hypertension and Outcomes Research from Clinical Trials to Clinical Epidemiology

Bruce M. Psaty, David S. Siscovick, Noel S. Weiss, Thomas D. Koepsell, Frits R. Rosendaal, D. Y. Lin, Susan R. Heckbert, Edward H. Wagner, Curt D. Furberg

American Journal of Hypertension

Article2011

Membrane proteins: from bench to bits

Gunnar Von Heijne

Biochemical Society Transactions

Chapter in a book2023

Neuroimmune interactions: From bench to bedside

Christina Alves Peixoto, Michael Maes, Igor Henrique Rodrigues de Paiva, Ingrid Prata Mendonça, Michel Gomes de Melo, Eduardo Duarte-Silva